Dow Dips Over 400 Points; JD.com Posts Upbeat Q3 Results

Impact · against what's priced in

JD.com's strong Q3 beat provides a positive catalyst for the stock, while Mersana Therapeutics and NVVE see significant price spikes driven by acquisition and momentum news, respectively.

MRSN+1.00

No priced-in read yet

In context

The shares surged 205% following the announcement that the company is being acquired by Day One Biopharmaceuticals.

Read from the article alone

Actual

• earnings▲6%
• oil
• JD
• MRSN
• NVVE
• china
• commodities
• e commerce
• health care
• market summary